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ABStrACt
Abnormalities of chromosome 10 are frequently observed in the development of medul‑
loblastoma, the most common malignant brain tumor of childhood. To identify critical 
genetic loci involved, we performed detailed physical mapping of regions of allelic 
loss on this chromosome. 18% of cases (5/32 primary tumors, 2/8 cell lines) harbored 
allelic losses on 10q. Refined mapping identified a 21.7Mb common interval, affecting 
the region 10q23.3‑10q25.3. This region contains three genes, MXI1, SUFU and BTRC, 
which represent putative medulloblastoma tumor suppressor (TS) genes on the basis of 
either (i) negative regulation of critical medulloblastoma pathways, or (ii) mutation in other 
cancer types. We therefore sought evidence of their genetic inactivation in 46 cases, by 
mutational analysis of their entire coding regions. A MXI1 mutation was identified which 
abolishes its translation initiation site (A1G; MET1VAL), however no further tumor‑specific 
sequence variations were detected. We next identified and characterised CpG islands 
associated with 5' regions of the MXI1, SUFU and BTRC genes; analysis of these regions 
for evidence of DNA hypermethylation, alongside expression analysis of their respective 
transcripts, revealed no evidence to support epigenetic inactivation of any gene. These 
findings implicate the inactivation of critical TS loci at 10q23.3‑25.3 in medulloblastoma, 
however comprehensive analysis of SUFU, BTRC and MXI1 indicates they are unlikely to 
represent major targets of these allelic losses. MXI1 mutation appears to play a role in the 
pathogenesis of a small subset of cases, and suggests an alternative mechanism to MYC 
amplification for disruption of the MYC/MAD/MAX network in medulloblastoma.
IntroDuCtIon
Medulloblastoma is an invasive embryonal tumor of the cerebellum, and the most 
common malignant brain tumor of childhood. Current five-year survival rates are around 
70%, however, the intensive therapeutic regimes employed often lead to long-term 
neuroendocrine and cognitive dysfunction.1,2 A better understanding of the molecular 
processes underlying medulloblastoma tumorigenesis offers the potential for more effective 
therapeutic strategies, through (i) the identification of molecular markers of prognosis for 
use in optimised therapeutic stratification, and (ii) the development of molecular-targeted 
therapies.
Cytogenetic and molecular cytogenetic studies of medulloblastoma have identified a 
number of nonrandom chromosomal gains and losses, indicative of the genetic locations 
of oncogenes and TS genes important in its tumorigenesis. The most frequent aberration 
is gain of 17q, usually by formation of an isochromosome 17q, occurring in 30–50% of 
primary tumors. Other common genetic changes include loss of chromosomes 8, 9, 10q, 
11, 16q and 17p and gains of chromosome 7.1,2 However, the molecular basis of medul-
loblastoma development is otherwise poorly understood, and gene-specific defects have 
only been identified in small subsets of cases.
Defects of chromosome 10 are a common feature of medulloblastoma. Combined 
results from conventional comparative genomic hybridization (CGH) studies have identi-
fied chromosome 10 defects in 39% of medulloblastomas overall, comprising isolated 
losses of 10p and 10q elements in 3% and 18% of tumors, respectively, and loss of the 
whole of chromosome 10 in a further 18% of cases.3-7 Chromosome 10 losses characterise 
a range of other tumor types, including cancers of the prostate,8 colon,9 endometrium,10 
bladder11 and brain,12-14 and have been associated with aggressive disease in certain 
cases.8,9,11,12,15 Physical mapping and chromosomal transfer studies support the presence 
of multiple tumor suppressors (TS) loci on both the p- and q-arms of chromosome 10 in 
these tumors8,16-19 and, moreover, a number of genes with either established or putative 
TS roles have been identified on this chromosome (e.g., PTEN/MMAC1, MXI1, LGI1, 
BTRC, SUFU and DMBT1).20-25
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Despite this, the critical loci targeted by chromosome 10 losses in 
medulloblastoma remain to be defined. Conventional CGH mapping 
techniques offer only limited resolution and cannot be readily applied 
to detailed physical mapping of critical chromosomal regions and/or 
identification of candidate genes.3-7 Furthermore, our recent demon-
stration of a widespread involvement for copy number-neutral allelic 
losses in medulloblastoma indicates that mapping studies restricted 
to the detection of copy number defects may underestimate rates 
of genetic loss in this disease.26 Thus, physical mapping studies of 
chromosome 10, which are capable of discerning allelic losses, are 
required to identify critical loci, however such studies in medul-
loblastoma have so far been restricted to small cohorts, low marker 
densities or have assessed limited sub-chromosomal regions.27-31
We have therefore undertaken a detailed mapping approach to 
identify critical regions of allelic loss of heterozygosity (LOH) on 
chromosome 10 in a cohort of 40 medulloblastomas, using an exten-
sive panel of polymorphic microsatellite markers. Refined mapping 
of identified allelic losses revealed a 21.7Mb common region of loss 
at 10q23.3-10q25.3, which contains the BTRC, SUFU and MXI1 
candidate TS genes. To assess any potential TS role(s) for these genes 
in medulloblastoma, we report the results of a comprehensive analysis 
of all three genes, to look for evidence of their inactivation by genetic 
and/or epigenetic mechanisms in these tumors.
MAtErIAlS AnD MEthoDS
Cell lines. Eight medulloblastoma cell lines were studied: D341 
Med, D384 Med, D425 Med, DAOY, D283 Med, MHH-Med-1, 
MHH-Med-8A and D556 Med.32 The identity of the cell lines 
was confirmed prior to use by karyotype analysis (data not shown). 
Cell lines were cultured under recommended conditions. DNA was 
extracted using the QIAGEN DNeasy kit (QIAGEN), and RNA 
with TRIzol (Invitrogen). RNA was treated with deoxyribonuclease 
(Ambion) to eliminate any contaminating DNA.
Primary tumors and control tissues. Forty-nine primary medul-
loblastomas were investigated in total. Briefly, the cohort comprised 
33 male and 16 female patients, of average age 9.1 years (range 
1.5–39.0 years). The majority of tumors were classified histopatho-
logically33 as classic [92% (n = 45)], although examples of large 
cell/anaplastic (LC/A) tumors [4% (n = 2)], noclular/desmoplastic 
(N/D) medulloblastoma [2% (n = 1)] and medulloblastoma with 
extreme noclucurity (MBEN) [2% (n = 1)] were also investigated. 
Classification of metastatic stage (according to Chang’s criteria34) 
was available for 32 cases, comprising 29 and 3 patients of meta-
static stages M0/1 and M2, respectively. Paired peripheral blood 
samples were collected for 32 of the tumor cases. Three control 
cerebellar samples comprised post-mortem material from patients 
who had died of nonneoplastic conditions. DNA was extracted 
from snap-frozen tissues by the TRIzol method (Invitrogen), and 
from formalin-fixed, paraffin-embedded tissue using the Nucleon 
hard tissue kit (Nucleon Biosciences). Constitutional DNA was 
extracted from blood samples by the Nucleon II method (Nucleon 
Biosciences). Unmatched normal peripheral blood DNA controls 
consisted of 100 newborn cord blood DNAs (from the North 
Cumbria Community Genetics Project, UK.). Local Research Ethics 
Committee approval was obtained for the collection, storage and 
biological study of all material.
PCR. Polymerase chain reactions (PCRs) were performed using 
AmpliTaq Gold® DNA polymerase (Applied Biosystems). For fragment 
analysis, conditions were as follows: 1x PCR Gold buffer, 0.2 mM of 
each dNTP (dA,C,T,GTP; Amersham Biosciences), 1.5 mM MgCl2, 
0.75 Units DNA polymerase, in a 10 ml final reaction volume. For 
RT-PCR and PCR prior to DNA sequence analysis, the final concen-
trations of PCR components were: 1x PCR Gold buffer, 0.2 mM 
for each dNTP (Amersham Biosciences), 1.5 mM MgCl2, 1.5 Units   
DNA polymerase, 1mM of each primer in a 25 ml reaction volume. 
PCRs were performed in a GeneAmp PCR System 9700 thermocy-
cler (Applied Biosystems), as follows: 96˚C, 10 min; 40 cycles (96˚C, 
1 min; 57˚C, 1 min; 72˚C, 1 min); 72˚C, 10 min. PCR primers and 
input DNA concentrations used for all PCR reactions are described 
in the following sections. Variations in cycle number and annealing 
temperature are detailed in the Supplementary Data Table.
Polymorphic microsatellite markers. Allelotype analysis was 
performed using polymorphic markers from Version 10 of the 
CHLC/Weber Human Screening Set developed at the Marshfield 
Institute (www.marshfieldclinic.org/research/genetics/).35 
Fluorescently-labeled primers from these sets were obtained from 
Research Genetics (Invitrogen Corporation) as MapPairs® Primers. 
Primer sequences for additional markers were obtained from the 
UniSTS database on the NCBI web-site (www.ncbi.nlm.nih.gov/) and 
fluorescently-labeled primers ordered from Proligo (Paris, France). The 
locations of markers on chromosome 10 are given according to Build 
36 of the NCBI Genomic Sequence Assembly. Additional markers 
associated with specific candidate TSGs were: PTEN, D10S1765; 
BTRC, D10S1239; SUFU, D10S1697; MXI1, D10S173; DMBT1, 
D10S1421.
PCR fragment analysis. Multiplex PCR reactions were performed 
as described above, with up to three primer pairs used per reaction. 
For optimisation, each primer pair was initially used at a final 
concentration of 0.24 mM. Primer concentrations were then varied 
to balance the amount of PCR product generated by each primer 
pair within a given multiplex. Either 1 ng or 25 ng input DNA 
was used, following initial optimisation of each multiplex reaction. 
Multiplex PCR conditions are summarised in the Supplementary 
Data Table. PCR products were run on a Beckman CEQTM8000XL 
DNA Analysis System according to the manufacturer’s instructions 
(Beckman Coulter). 0.5 ml PCR product and 0.3 ml DNA size 
standard-400 were added to 40 ml sample loading solution in a 96 
well plate. Automated capillary electrophoresis was then performed 
using the Frag-3 program, and fragment analysis performed using 
CEQ8000 software (all Beckman Coulter).
LOH analysis. Methods used for the assessment of LOH in 
cell lines have previously been described; briefly, the observation 
of homozygosity at 5 or more adjacent polymorphic microsatellite 
markers was consistent with LOH in the encompassing region.26 
For analysis of LOH using paired tumor (T) and blood (B) DNA 
samples, CEQ8000 software was used to calculate the peak height 
ratios of informative samples (i.e., samples heterozygous in their 
constitutional DNA) for each marker, as (T1/T2)/(B1/B2), where 
T1 and T2 are the peak heights of the two alleles in the tumor 
sample, and B1 and B2 represent the corresponding alleles in the 
constitutional sample. Markers producing a single homozygous 
peak in the constitutional DNA sample were designated nonin-
formative. To assign cut-off values for retention of heterozygosity 
(ROH) or LOH, the level of normal inter-assay variation observed 
in peak height ratios was first assessed. Nineteen constitutional 
DNA samples were independently analysed twice using 9 different 
microsatellite markers. Using these data, the peak height ratios 
observed from the two independent analyses [i.e., (B1/B2) Analysis 
1 / (B1:B2) Analysis 2] were obtained for a total of 134 hetero-
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zygous samples. A normal probability plot and Shapiro-Wilk test 
for normality indicated that the logged data followed a normal 
distribution (mean, -0.057; standard deviation, 0.23), with the 
exclusion of 1 sample. For subsequent LOH analysis of paired tumor 
and constitutional DNA, the probability of each logged peak height 
ratio belonging to the normal distribution was assessed. Ratios with 
a probability >0.01 were assigned as ROH and those <0.00001 were 
designated as LOH. These cut-offs were approximately equal to 2.5 
and 4.5 standard deviations from the mean, respectively. Intermediate 
values were called as noninformative.
DNA sequence analysis. The coding regions of candidate TS 
genes were screened for evidence of DNA sequence variations by 
denaturing high-performance ligand chromatography (dHPLC), 
followed by direct DNA sequence analysis. PCR primers used to 
amplify each coding exon, along with flanking intronic sequences, 
are described in the supplementary data table. PCRs were performed 
as described above, using 50 ng genomic DNA as template. To allow 
the formation of heteroduplexes prior to dHPLC, PCR products 
were denatured at 95˚C for 5min then cooled to 4˚C at the rate of 
1˚C per 2min in a thermal cycler. For the detection of homozygous 
mutations, samples were ‘spiked’ with PCR product from a wild-type 
sample at a ratio of 1:1, prior to heteroduplex formation. dHPLC was 
carried out using the Transgenomic WAVE® system (Transgenomic, 
Cheshire, UK). Prior to analysis, PCR amplicons were analyzed 
using the associated Wavemaker software package to estimate the 
optimal temperature, run time and acetonitrile gradient. PCR 
products were injected by the autosampler at a constant flow rate of 
0.9 ml/min and were eluted from the solid phase, which consisted of 
a DNASep analytical column, with a binary gradient of 0.1 M triethy-
lamonium acetate (Buffer A) and 0.1 M TEAA/25% acetonitrile 
(Buffer B). Samples with elution profiles differing from those of 
wild-type controls were subjected to direct DNA sequence analysis. 
DNA sequencing analysis was performed on purified PCR products 
(QIAGEN gel extraction kit) on a Beckman CEQ8000XL DNA 
Analysis System (Beckman Coulter), according to the manufacturer’s 
instructions.
Analysis of promoter methylation status. Promoter-associated 
CpG islands were identified and characterised using the Emboss 
CpGPlot website (www.ebi.ac.uk/emboss/cpgplot/). The methylation 
status of the  SUFU, BTRC and MXI1 CpG islands was determined by 
methylation specific PCR (MSP)36 and combined bisulphite restric-
tion analysis (COBRA)37 of bisulphite-treated DNA. Bisulphite 
treatment was carried out using a CpG genome DNA modification   
kit (Serologicals, Livingston, UK), according to the manufacturer’s    
instructions. For MSP, PCR amplification of bisulphite-treated 
DNA was performed using primers designed to specifically bind 
either unmethylated or methylated DNA after bisulphite treatment. 
20 ng bisulphite-treated DNA was used as template per MSP reac-
tion. PCR primers and conditions are provided in the supplementary 
table. The unmethylated control for MSP consisted of pooled normal          
neonatal cord blood DNA (from the North Cumbria Community 
Genetics Project, UK), the methylated control used was universally     
methylated DNA (Serologicals, Livingston, UK). COBRA of the 
predicted SUFU, BTRC and MXI1 CpG islands was performed 
following PCR-amplification of 20 ng bisulphite-treated DNA, using 
primer sets which recognise both methylated and unmethylated 
DNA sequences (see supplementary data table). PCR products were 
digested overnight with the TaqI restriction enzyme (New England 
Biolabs) at 65˚C (SUFU and BTRC analyses). MXI1 was addition-
ally digested overnight with the BstU1 restriction enzyme (New 
England Biolabs), also at 65˚C. If methylated cytosines are contained     
within its restriction sites, the TaqI restriction enzyme generates three 
fragments of 116, 63 and 63 bp from the SUFU PCR product and 
three fragments of 160, 62 and 31 bp for BTRC. TaqI and BstUI cut 
the 151 bp PCR product of methylated MXI1 once each, creating 
three fragments of 72, 40 and 39 bp.
5‑aza CdR treatment. Three cell lines (D425 Med, MED-8A, 
and D283 Med) were grown in the presence or absence of the        
demethylating agent 5-aza-2-deoxycytidine (5-Aza CdR (5   mM)) 
for three days. Medium was renewed daily. RNA was extracted from 
107 cells using an RNeasy kit (QIAGEN). RNA concentration was        
determined by spectrophotometry, and agarose gel electrophoresis      
was used to confirm consistent RNA integrity and quantity.       
Semi‑quantitative RT‑PCR. cDNA was synthesised using the 
SuperScript™ First-Strand Synthesis System for reverse transcrip-
tion-PCR (RT-PCR) (Invitrogen). One microgram of RNA was 
reverse transcribed following the protocol for first-strand synthesis, 
using oligo(dT) primers, according to the manufacturer’s instructions. 
RT-PCR amplification conditions for each target gene were selected 
such that the cycle numbers used were within the exponential phase 
of amplification (data not shown). Primer sequences and PCR 
conditions are shown in the Supplementary Data Table. GAPDH, 
a housekeeping gene, was used as a control for RNA integrity and 
quantity.38
rESultS
High‑density mapping of allelic losses (LOH) on chromosome 
10 in medulloblastoma. Initial mapping analysis was performed 
in 40 medulloblastoma samples (32 primary tumor/constitutional 
DNA pairs and eight cell lines), using a panel of 22 polymorphic 
microsatellite markers, spaced at an average physical interval of 
~6Mb along chromosome 10. Markers were from version 10 of the 
Marshfield Institute Human STRP Screening Set, supplemented 
with additional markers specific to loci containing the candidate 
TSGs; PTEN, BTRC, SUFU, MXI1 and DMBT1 (see Materials and 
Methods). Representative analyses from primary tumors are shown 
in Figure 1A.
Six (19%) of the 32 primary tumors examined showed evidence 
of allelic loss on chromosome 10 which affected at least one marker 
(Fig. 1B). Of these, instances of isolated loss of 10p and 10q regions 
were detected in 3% (1/32) and 16% (5/32) of cases, respectively, 
while no evidence of whole chromosome loss was observed. Two of 
the 8 cell lines examined harbored detectable regions of allelic loss; 
loss of the whole of chromosome 10 was detected in DAOY while, 
in D425Med, the q-arm alone was lost (Fig. 1B).
Two minimal regions of allelic loss were identified, suggesting 
the locations of candidate TS loci for medulloblastoma. First, a 
common region, which was affected by all allelic losses involving the 
q-arm. In the initial mapping analysis, this region covered approxi-
mately 30 Mb, with breakpoints defined by markers D10S2470 
to D10S1421 in tumors NMB64 and NMB79. Refined mapping 
of the regions of allelic loss in these two tumors, using a further 
12 polymorphic markers, narrowed down the minimal region 
to a 21.7 Mb interval, extending from D10S583 (94.4 Mb) to 
D10S1237 (116.1 Mb) at 10q23.3-10q25.3 (Fig. 1C). Second, a 
case of isolated allelic loss was observed on 10p which affected a 
single microsatellite marker (D10S1208), with its boundary defined 
by marker D10S1462, suggesting the involvement of a chromo-
somal region at the centromeric end of 10p [10p(cen)-p12.1] in a 
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small subset of medulloblastomas. 
However, in view of its relative 
infrequency of loss, this region was 
not investigated further.
Associations with clinical and 
pathological disease features. A 
detailed analysis of relationships 
between 10q allelic losses and 
clinico-pathological disease features 
was not appropriate in this retro-
spectively-collected cohort, or in 
view of the frequency of losses 
observed. On initial analysis, 10q 
allelic losses appeared to characterize 
the full range of clinical and patho-
logical disease sub-types examined, 
and were observed in tumors of 
classic (n = 3), LC/A (n = 1) and 
MBEN (n = 1) histopathology; 
male (n = 3), female (n = 2); infant 
(<3 yrs; n = 1) and childhood 
(3–16 yrs; n = 3) cases; and patients 
of M0/1 (n = 3), M2 (n = 1) 
and unclassified (n = 1) metastatic 
stage. The single case of 10p allelic 
loss observed occurred in a M0/1 
classic tumor from a male patient 
aged 12.6 years.
Comprehensive analysis 
of BTRC, SUFU and MXI1 as 
candidate medulloblastoma TS 
genes. The 21.7 Mb minimal 
region of allelic loss identified at 
10q23.3-10q25.3 (94.4 Mb to 
116.1 Mb) contains three puta-
tive TS genes (BTRC, SUFU and 
MXI1), which are each further 
implicated as critical medullob-
lastoma genes by the proposed 
functions of their gene products. 
BTRC and SUFU are negative 
regulators of the Wnt/Wingless and 
Hedgehog signalling pathways,39 
while MXI1 controls activity of the 
MYC family of protooncogenes,40 
all of which systems play funda-
mental roles in medulloblastoma 
development.41-43 We therefore 
undertook a detailed analysis of 
all three candidate genes, to assess 
their potential roles as medulloblas-
toma TS genes, by seeking evidence 
of their genetic and/or epigenetic 
inactivation.
Genetic inactivation: assessment 
of DNA sequence variations. The 18 
exons which encompass the SUFU 
and MXI1 coding regions (including 
their intron/exon boundaries; see 
Materials and Methods) were assessed 
Figure 1. Identification and mapping of allelic losses on chromosome 10 in medulloblastoma. (A) Assessment 
of allelic losses on chromosome 10 by multiplex PCR and fragment analysis of polymorphic microsatellite 
markers, illustrated for paired tumour (NMB98T) and control constitutional (NMB98B) DNA samples derived from 
a single patient. Alleles detected using three independent microsatellite markers are shown (GATA121A08, blue; 
D10S1412, green; D10S1425, black), alongside a size marker reference (red), following automated capillary 
electrophoresis on a Beckman CEQTM8000XL DNA Analysis System (Beckman Coulter). Allelic status for each 
marker was calculated, based on allele peak height ratios determined for constitutional (B1, B2) and tumour 
(T1, T2) DNA samples, as described in materials and methods. Note LOH at marker D10S1425 in this tumour, 
and ROH at GATA121A08 and D10S1412. (B) Allelic losses observed in a cohort of medulloblastoma cell 
lines (n = 8) and primary tumours (n = 32), shown alongside a cytogenetic and physical map of chromosome 
10 (based on Build 36 of the NCBI Genomic Sequence Assembly). Two cell lines and six tumours demonstrated 
evidence of allelic loss, and are shown. For cell lines, heterozygous markers are represented by open circles, 
and homozygous / hemizygous markers by closed circles. A disproportionately small second peak rendered 
marker GATA121A08 noninformative in D425Med. Continuous regions of homozygosity/hemizygosity affecting 
≥5 adjacent markers were defined statistically as allelic loss.26 For tumors, open circles denote ROH, closed 
circles represent LOH and grey circles correspond to noninformative markers. For all samples, thick black lines 
show the extent of the regions of loss detected in each case. (C) Refined mapping of the common region of loss 
identified at 10q23‑q26 in cases NMB64 and NMB79, using 12 additional polymorphic microsatellite markers 
(indicated in bold). Note the 21.7 Mb minimal region defined by markers D10S583 and D10S1237, containing 
the candidate TS genes, BTRC, SUFU and MXI1.
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for evidence of sequence variations in a series of 46 medulloblastomas 
(38 primary tumors and 8 cell lines), by dHPLC screening and direct 
DNA sequence analysis. Mutation detection using these combined 
methods has been reported to detect >95% of sequence variations.44 
Assessed MXI1 regions encompassed exons encoding all three 
predicted alternative transcripts corresponding to the murine splice 
variants Mxi1‑SRa, Mxi1‑SRb and Mxi1‑WR.45 The transcripts 
related to Mxi1‑SRa and Mxi1‑WR have not previously been assessed 
for mutations in human malignancies. BTRC was not investigated 
for sequence variations, since two independent studies have failed to 
identify mutations in this gene in a combined cohort of 98 primary 
medulloblastomas.46,47
A missense mutation in MXI1 was discovered in the D556Med 
medulloblastoma cell line (Fig. 2A and B). This nucleotide substitu-
tion (A1G; Met1Val) is predicted to disrupt the MXI1 translational 
start codon, and was not present in 100 normal chromosomes or SNP 
databases (dbSNP; www.ncbi.nlm.nih.gov/). No evidence of SUFU 
mutations was found in any case. Three SUFU polymorphisms 
(comprising a coding (Ala340Ser) and two intronic variations), and 
three MXI1 polymorphisms (a silent coding and two intronic varia-
tions) were identified in medulloblastoma samples. The polymorphic 
nature of each of these variations was confirmed by their presence 
in either (i) a corresponding paired constitutional DNA sample, 
(ii) a panel of 200 normal chromosomes or (iii) dbSNP. Results are 
summarized in Figure 2A.
Epigenetic inactivation: CpG island identification, methylation 
status and transcriptional silencing. CpG islands were identified at 
the 5' ends of the MXI1, SUFU and BTRC genes, using CpGPlot 
software (www.ebi.ac.uk/emboss/cpgplot/), and are summarized in 
Figure 3. Analysis of the methylation status of each CpG island was 
then performed in a cohort of 35 medulloblastomas (28 primary 
tumors and 8 cell lines), using two independent assays; MSP and 
COBRA. Using these parallel approaches, no evidence was found 
to support hypermethylation of the CpG islands associated with the 
MXI1, SUFU and BTRC genes in any sample analysed. Results are 
illustrated in Figure 4A and B.
To further assess any role for epigenetic mecha-
nisms in the inactivation of MXI1, SUFU and BTRC 
in medulloblastoma, we next performed mRNA 
expression analysis of all three genes in a panel of 
eight medulloblastoma cell lines, in comparison with 
normal cerebellar samples (n = 3), by semi-quan-
titative RT-PCR. Until recently, human MXI1 has 
been studied as a single transcript, corresponding 
to the murine Mxi1-SRb transcript. As part of this 
study, the expression of three human isoforms which 
correspond to previously described alternative murine 
transcripts, Mxi1‑SRa, Mxi1‑SRb and Mxi1‑WR,45 
was confirmed by RT-PCR (data not shown). These 
three transcripts were represented by cDNA clones 
(NCBI/Genbank accession numbers are given) 
L07648 (MXI1-SRb), BC012907 (MXI1-WR) and 
BC035128 (MXI1-SRa). Expression levels observed 
in the cell line panel for MXI1, SUFU and BTRC 
were comparable to those detected in the normal 
cerebellum, with no evidence of transcriptional silencing 
observed for any of the candidate genes examined (Fig. 
4C). Furthermore, treatment of a subset of these cell 
lines (n = 3; D283Med, D425Med, MHH-MED-8A) 
with a DNA methyltransferase inhibitor (5-azaCdR) 
did not reveal any evidence of methylation-dependent transcriptional 
silencing for any gene (data not shown). Comparable results were 
found for all three MXI1 isoforms tested (data not shown).
Taken  toge the r,  the s e  da t a 
indicate that CpG island hypermethylation and methyla-
tion-dependent transcriptional silencing of MXI1, SUFU and 
BTRC are not significant features of medulloblastoma development.
DISCuSSIon
Molecular cytogenetic studies of medulloblastoma have consis-
tently demonstrated loss of chromosome 10 elements in about one 
quarter of all tumors,3-7 suggesting that one or more critical medul-
loblastoma TS genes are likely to reside on this chromosome. The 
present study was undertaken in order to define and map in detail           
the region(s) of chromosome 10 which are commonly lost in medul-
loblastoma tumors, and to determine whether candidate TS genes in 
these regions show evidence of inactivation by genetic or epigenetic 
mechanisms.
Whereas evidence of isolated allelic loss on 10p was only 
observed in a single case (1/32 primary tumors), losses specifically 
affecting 10q regions were common in our cohort [5/32 (16%) of          
primary cases]. Subsequent detailed physical mapping identified a 
minimal region of loss at 10q23.3-10q25.3, extending from markers 
D10S583 to D10S1237. Although previously published conven-    
tional CGH studies in medulloblastoma have not yielded detailed 
physical mapping information, they nonetheless provide an informa-
tive comparator for our current results. A meta-analysis of previous 
large-scale CGH studies (i.e., greater than 20 tumors studied,3-7,64 
alongside results from this study and a recent array-CGH study 
in medulloblastoma,48 revealed consistent findings (Fig. 5); while 
10p loss is rare, 10q losses occurred in 39/247 (16%) of tumors 
overall, with a further 23/247 (9%) demonstrating loss of the whole 
chromosome.
Our data indicate that genetic losses on chromosome 10q 
characterize all major clinical and histopathological medulloblastoma 
Figure 2. DNA sequence variations in SUFU and MXI1 in medulloblastoma. (A) Summary 
of sequence alterations identified in SUFU and MXI1 in medulloblastoma cell lines (n = 8) 
and primary tumours (n = 38), by dHPLC and direct sequence analysis. Nature of variation: 
a, variation reported in dbSNP (www.ncbi.nlm.nih.gov/); b, variation identified in paired 
constitutional (blood) DNA sample; c, variation identified in a panel of 200 normal chromo‑
somes; d, variation not identified in 100 normal chromosomes. Nucleotide and amino acid 
positions correspond to Genbank gene IDs 4601 (MXI1) and 51684 (SUFU). (B) Direct DNA 
sequence chromatograms showing the mutation detected in exon 1 of MXI1 in the D556Med 
cell line. This A>G variation is predicted to disrupt the translational start codon by causing a 
methionine to valine amino acid substitution.
www.landesbioscience.com Cell Cycle 2385
Chromosome 10 Loss in Medulloblastoma
sub-types, however the limited retrospectively-collected 
nature of our cohort precludes further detailed analysis. 
To date, only one study has assessed 10q losses in medul-
loblastoma in this fashion. Using fluorescence in situ 
hybridisation methods and a probe to the 10q24.31 
region, we previously investigated 10q losses in a patient 
cohort derived predominantly from cases registered on 
the recent PNET3 study.41 These independent results 
are consistent with the present study; 10q losses were 
detected in 15% of cases overall, but did not show a 
significant relationship to any clinical or patholog-
ical (including histopathological sub-type and overall 
survival) variable tested.41 The clinico-pathological and 
biological significance of 10q loss in medulloblastoma 
thus remains to be established by wider analysis in 
further extensive or uniformly treated cohorts, along-
side the determination of any relationships to other 
established genetic and epigenetic features of medullob-
lastoma development.
The common interval of genetic loss identified at 
10q23.3-10q25.3 contains three genes, MXI1, SUFU 
and BTRC, which represent putative medulloblastoma 
TS genes on the basis of either (i) negative regulation 
of critical pathways associated with MB development, 
or (ii) mutation in other cancer types. We therefore undertook a 
detailed genetic and epigenetic analysis of each gene to assess any 
potential TS role(s) in medulloblastoma.
MXI1 (Max interactor 1), a candidate TS gene located at 
10q24-q25, negatively regulates activity of the protein products of 
the MYC protooncogene family, which promote cellular processes 
including apoptosis and cell cycle progression.49,50 MYC and MYCN 
oncogene activation by amplification is seen in 10–15% of medul-
loblastomas, and is associated with poor prognosis.41,51 Additionally, 
MYC genes can be transcriptionally upregulated as targets of the 
Wnt/Wingless and Hedgehog pathways, which are commonly acti-
vated in medulloblastoma development.39,52,53 Thus, dysregulation 
of MYC activity appears to be important in medulloblastoma forma-
tion, and inactivation of the MXI1 tumor suppressor gene could 
feasibly impact on this. Inactivating mutations of MXI1 have been 
previously reported in prostate carcinomas.54,55
In this study, we identified a single tumor-specific MXI1 coding 
mutation among 46 medulloblastoma tumors and cell lines tested. 
These findings are consistent with those from a separate study of 
22 medulloblastomas, in which no MXI1 mutations were found51 
and suggest that, although rare,    MXI1 mutations could play a role 
in a small subset of cases. The mutation identified (A1G; Met1Val)  
eliminates the translation start site in transcripts generated from 
the mutated allele, and can thus be predicted to exert two potential 
pro-tumorigenic effects, either through removal of repressor activity 
by obliteration of MXI1 translation, or through usage of alterna-
tive translational initiation sites giving rise to variant isoforms with 
altered activities.
Investigations of human MXI1 have generally been restricted to 
analysis of a single transcript, corresponding to the murine Mxi1-SRb 
transcript, however the recent description of additional MXI1 
isoforms suggests a more complex situation. Murine Mxi1 has three 
characterised splice variants: Mxi1‑SRa, Mxi1‑SRb and Mxi1‑WR. 
The isoforms each have different first exons, resulting in the pres-
Figure 3. Identification of CpG islands associated with the MXI1, SUFU and BTRC genes. 
(A) Plot showing the location of a CpG island identified at the BTRC locus using CpG 
plot software (www.ebi.ac.uk/emboss/cpgplot). This predicted CpG island associated 
with the BTRC promoter region is 277bp in length, and is represented by a shaded box. 
Nucleotide positions are shown relative to the position of the BTRC translational start 
codon, which is contained within the predicted island. The position of coding exon 1 of 
the BTRC gene is also marked. (B) Table summarizing promoter‑associated CpG islands 
identified for SUFU, BTRC and MXI1. CpG islands were defined by the parameters shown, 
with the minimum criteria being (i) size greater than 200bp, (ii) observed/expected ratio 
of the frequency of dinucleotide CpG of >0.6 and (iii) an overall C/G content of >50%. 
Positions of these CpG islands on chromosome 10 are shown relative to NCBI assembly 
36 of the human genome sequence.
Figure 4. Epigenetic analysis of    BTRC, SUFU and MXI1 in medulloblastoma. (A) MSP 
analysis of CpG island methylation status in primary medulloblastomas, illustrated for 
BTRC. PCR products were amplified from bisulphite‑treated DNA, using primer sets specific 
for methylated (M) or unmethylated (U) sequences within the CpG island. The methyl‑
ated control (Meth) was universally‑methylated DNA; the unmethylated control (Unmeth) 
consisted of pooled DNA from normal neonatal cord blood samples. (B) COBRA analysis 
of CpG island methylation status in primary medulloblastomas, illustrated for BTRC. PCR 
products were amplified from bisulphite‑treated DNA, using primer sets which recognise 
both methylated and unmethylated sequences. Digestion of PCR products using the TaqI 
restriction endonuclease was then used to discriminate between methylated and unmethyl‑
ated sequences. U, undigested PCR product; D, TaqI digested PCR product. In methylated 
samples, TaqI cuts twice within the 253 bp PCR product, generating three fragments 
of 160, 62 and 31 bp. The enzyme does not digest unmethylated samples. The minor 
bands observed (<60 bp) represent primer dimers. For (A and B), consistent results were 
observed in replicate analyses. No evidence of methylation was observed for any gene 
in any case, using either method of analysis. (C) Semi‑quantitative mRNA expression   
analysis of BTRC, SUFU and MXI1 by RT‑PCR, in eight medulloblastoma cell lines and       
three normal cerebellar samples, shown alongside a GAPDH control for RNA loading 
and integrity. Treatment of three cell lines (marked **) with a DNA methyltransferase 
inhibitor (5‑azaCdr) did not reveal any evidence of methylation‑dependent increases in 
gene expression (data not shown).
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ence or absence of a SID (transcriptional repressor) domain. A SID 
is present in Mxi1-SRb and Mxi1-SRa, but absent in Mxi1-WR. 
As a result, the first two isoforms are strong transcriptional repres-
sors and the third is a weak repressor with repressive activity ranked 
as Mxi1-SRa > Mxi1-SRb > Mxi1-WR.45 As part of the current 
study, the existence of human splice variants corresponding to those 
characterized in the mouse was confirmed.
Multiple human isoforms have also been described for MXI1 on 
the Ensembl and NCBI sequence databases, and by Engstrom et al56 
and Kawamata et al.57 Together, these results indicate that there are 
human transcripts with and without the DBD encoded by exon 3.58 
As would be expected from established mechanisms of MXI1 action, 
presence or absence of the DBD is reported to affect the activity 
of the proteins and could, in theory, impact upon its regulation 
of MYC protein activity.49,57 However, the number and structure 
of these human splice variants have not been clearly characterised, 
and their detailed investigation was beyond the current study. More 
comprehensive studies are now required to define the expression and 
biological relevance of MXI1 splice variants in medulloblastoma. The 
identification of a MXI1 mutation in medulloblastoma, coupled with 
established roles for MYC and MYCN amplification, underline the 
potential importance of the MYC/MAD/MAX network in medul-
loblastoma, and raise the possibility that further tumor-specific 
alterations affecting alternative members of this system may exist.
BTRC and SUFU negatively regulate the sonic hedgehog (SHH) 
and Wnt/Wingless (Wnt) signal transduction pathways, both of 
which promote cellular proliferation in the developing cerebellum, 
and play major roles in medulloblastoma development.39,59 Activating 
mutations affecting alternative components of both pathways are 
common events in medulloblastoma; PTCH1 and SMO mutations 
(SHH pathway) together occur in ~15% of medulloblastomas, while 
CTNNB1, APC and AXIN1 mutations (Wnt pathway) collectively 
characterise a further ~15% of cases.1 Further negative regulatory 
elements of these pathways, including BTRC and SUFU, thus 
Figure 5. Meta‑analysis of chromosome 10 losses in medulloblastoma. Combined results from independent studies (n = 8) involving more than 20 pri‑
mary tumors are shown. (1) Russo et al.;7 (2) Pan et al.;64 (3) Eberhart et al.;4 (4) Nicholson et al.;5 (5) Reardon et al.;6 (6) Avet‑Loiseau et al.;3 (7) This 
study; (8) Rossi et al.48 Conventional CGH techniques were used in all except this study (allelic losses) and that of Rossi et al.48 (array CGH). (A) Table 
showing the number of tumors studied, and numbers and percentages of whole chromosome loss and loss of specific 10q regions observed. (B) Regions of 
sub‑chromosomal loss detected in individual tumours, as depicted in figures from the publications. Each tumour loss is represented by a black line relative 
to its cytogenetic position (see adjacent ideogram), and corresponding study numbers are shown at the bottom of each line. Note that whole chromosome 
losses are not shown. (C1) Common regions of loss identified in (B), with the percentage of tumours in (B) which contain deletions of the common regions. 
(C2) Minimally overlapping regions of loss on chromosome 10 identified in the matrix‑CGH analysis of 47 tumours reported by Mendrzyk et al.,63 shown as 
percentages of the total number of chromosome 10 losses observed in this study. Results for individual tumours were not published.63 Approximate physical 
positions and locations of candidate TS genes are also shown.
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represent attractive candidate medulloblastoma TS genes. However, 
we failed to identify any somatic mutations in       SUFU in 46 medul-
loblastomas. These data are consistent with independent studies by 
Thompson et al.60 and Koch et al.,61 who reported SUFU mutations 
in 2% (1/46) and 0% (0/134) of tumors, respectively. Although 
Taylor et al46 identified truncating SUFU mutations in 9% (4/46) 
medulloblastomas, three of these represented germline alterations 
associated with medulloblastoma predisposition, and only one 
somatic mutation was reported. Thus, from these combined data, 
while germline mutations may be involved in medulloblastoma 
predisposition, somatic SUFU mutations only rarely play a role in the 
sporadic disease, affecting <1% of cases (2/272) overall. Two previous  
studies of BTRC sequence variation in medulloblastoma have failed 
to identify any mutations in a combined cohort of 98 tumors,46,47 
and hence its mutational status was not investigated further in the 
present study.
In view of the limited evidence to support MXI1, SUFU and 
BTRC as mutational targets, we sought evidence of their epigenetic 
inactivation in medulloblastoma. Tumor-specific hypermethylation 
events at promoter-associated CpG islands, which cause transcrip-
tional silencing, are an established feature of medulloblastoma 
development,62 however the epigenetic status of MXI1, SUFU and 
BTRC has not been investigated previously in any tumor type. CpG 
islands encompassing proximal regions of all three genes were there-
fore identified and characterized, and two alternative methylation 
detection methods developed for each gene (MSP and COBRA); no 
evidence of methylation was found using either method. Although 
we cannot rule out specific modifications at individual CpG residues, 
these data suggest that widespread hypermethylation of these CpG 
islands in medulloblastoma is rare. Previous studies indicate that 
medulloblastoma cell lines are representative models of epigenetic 
events detected in primary tumors;62 no evidence of methylation- 
dependent transcriptional silencing was observed for any gene 
examined in a panel of eight medulloblastoma lines. Although 
complementary expression data for primary tumors would be desir-
able, these data further support our hypermethylation findings and 
indicate that epigenetic transcriptional silencing of MXI1, SUFU and 
BTRC is not a common feature of medulloblastoma.
This comprehensive analysis of MXI1, SUFU and BTRC as 
candidate medulloblastoma TS genes indicates that alternative TS 
loci at 10q23.3-25.3 are likely to play a role in its development. 
Further mapping studies of extended cohorts, using high-resolution 
mapping methods, may help to elucidate more accurately the positions 
of critical regions of chromosomal loss. From our meta-analysis of 
chromosome 10 genetic losses in medulloblastoma, three separate 
regions define common regions of overlap (Fig. 5C1), supporting the 
presence of multiple TS loci on 10q in medulloblastoma. The most 
commonly lost region, deleted in 90% of tumors with regional loss, 
extends over 10q25, with two further common regions identified 
within 10q23-q24. However, these studies have employed various 
methodologies for the detection of chromosomal losses, and few have 
allowed detailed physical mapping. Two initial array-CGH studies 
in medulloblastoma confirm the future potential of array-based 
approaches for high-resolution mapping, and have identified putative 
minimal regions of loss at 10q24.3 (0.9 Mb,48 10q23.3 and 10q26.3 
(each 0.3 Mb63) defined by individual tumors, which now require 
further substantiation by independent studies, prior to detailed inves-
tigations of the genes harbored within.
In summary, our findings implicate the inactivation of TS loci 
at 10q23.3-25.3 in medulloblastoma. MXI1 and SUFU mutations 
may play a role in the development of small subsets of sporadic 
cases, however our data indicate that MXI1, SUFU and BTRC 
are unlikely to represent significant targets of 10q allelic losses in 
medulloblastoma, and suggest the presence of alternative TS genes at 
10q23.3-25.3, which play critical roles in its pathogenesis.
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